Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,405 Shares

Key Points

• EVP Tolga Tanguler of Alnylam Pharmaceuticals sold 1,405 shares at an average price of $452.05, totaling approximately $635,130, which represents a 4.87% decrease in his ownership.
• The company reported $0.32 earnings per share for the last quarter, exceeding the consensus estimate of ($0.54), with revenues reaching $773.69 million, up 17.3% year-over-year.
• Alnylam Pharmaceuticals has a market capitalization of $59.82 billion and is rated as a "Moderate Buy" by analysts, with an average price target of $439.58.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Tolga Tanguler sold 1,405 shares of the company's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $635,130.25. Following the transaction, the executive vice president owned 27,438 shares of the company's stock, valued at $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Tolga Tanguler also recently made the following trade(s):

• On Monday, August 18th, Tolga Tanguler sold 1,396 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY traded down $4.64 during trading on Friday, hitting $456.35. 969,084 shares of the company were exchanged, compared to its average volume of 982,632. The business's 50 day moving average is $439.02 and its 200-day moving average is $337.29. The company has a market capitalization of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Wealth Enhancement Advisory Services LLC lifted its position in Alnylam Pharmaceuticals by 94.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock valued at $2,957,000 after acquiring an additional 6,112 shares in the last quarter. Merit Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 113.0% in the 1st quarter. Merit Financial Group LLC now owns 5,314 shares of the biopharmaceutical company's stock valued at $1,435,000 after acquiring an additional 2,819 shares in the last quarter. Whipplewood Advisors LLC lifted its position in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares in the last quarter. Finally, TB Alternative Assets Ltd. bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $2,476,000. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on ALNY shares. BMO Capital Markets increased their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Citigroup increased their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, Scotiabank increased their price target on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $439.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.